FIELD: medicine. SUBSTANCE: method involves studying interpherone-α sera. Their concentration being equal to or greater than 160 pcg/ml, worsening clinical development course of the disease is to be predicted with high probability of metastases development. A like state being found to take place, corresponding immunocorrection treatment is carried out under immunological indices control. EFFECT: enhanced effectiveness in evaluating metastases risk and administering appropriate treatment.
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTING CLINICAL COURSE OF UVEAL MELANOMA DEVELOPMENT | 1999 |
|
RU2157998C1 |
METHOD FOR PREDICTING CLINICAL DEVELOPMENT COURSE OF UVEAL MELANOMA | 1998 |
|
RU2146823C1 |
METHOD OF REVEALING LATENT METASTATIC SPREAD IN PATIENTS WITH UVEAL MELANOMA | 1998 |
|
RU2147373C1 |
METHOD OF TREATING UVEAL MELANOMA | 2000 |
|
RU2169006C1 |
METHOD FOR PREDICTING CLINICAL COURSE OF UVEAL MELANOMA DEVELOPMENT | 2001 |
|
RU2197731C2 |
METHOD OF TREATING UVEAL MELANOMA | 2000 |
|
RU2175242C1 |
METHOD FOR PREDICTING CLINICAL DEVELOPMENT COURSE OF UVEAL MELANOMA | 2001 |
|
RU2192812C1 |
METHOD FOR PREDICTING CLINICAL FLOW OF UVEAL MELANOMA | 2001 |
|
RU2193200C1 |
METHOD FOR SETTING DIFFERENTIAL DIAGNOSIS OF LEIOMYOMA AND IRIS MELANOMA | 2001 |
|
RU2199124C1 |
METHOD FOR PREDICTING EXCESSIVE CICATRIX FORMATION AFTER ANTIGLAUCOMA OPERATIONS DONE | 2002 |
|
RU2227294C2 |
Authors
Dates
2000-05-20—Published
1999-03-24—Filed